Boston Scientific (BSP:B1SX34) Long-Term Debt: R$55,294 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1SX34 Boston Scientific Corp BSP:B1SX34
80 GF Score
Price R$67.48
GF Value R$137.33
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Long-Term Debt?

Boston Scientific BSP:B1SX34 +1.15% 80 Long-Term Debt is R$55,294 Mil as of Jun. 2026. GuruFocus rates BSP:B1SX34 with a GF Score™ of 80/100 and a GF Value™ of R$137.33 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Boston Scientific's Long-Term Debt for the quarter that ended in Jun. 2026 was R$55,294 Mil.

Boston Scientific's quarterly Long-Term Debt declined from Dec. 2025 (R$60,078 Mil) to Mar. 2026 (R$56,814 Mil) and declined from Mar. 2026 (R$56,814 Mil) to Jun. 2026 (R$55,294 Mil).

Boston Scientific's annual Long-Term Debt increased from Dec. 2023 (R$41,972 Mil) to Dec. 2024 (R$53,945 Mil) and increased from Dec. 2024 (R$53,945 Mil) to Dec. 2025 (R$60,078 Mil).

Boston Scientific  (BSP:B1SX34) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Boston Scientific Long-Term Debt Related Terms

Boston Scientific Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Long-Term Debt Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49,734.85 46,736.51 41,971.69 53,945.04 60,078.17

Boston Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60,898.43 58,955.46 60,078.17 56,814.37 55,294.16
BSP:B1SX34
80GF Score
Boston Scientific Corp BSP:B1SX34
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of R$55,294 Mil mean?
Boston Scientific (BSP:B1SX34) has a Long-Term Debt of R$55,294 Mil as of Jun. 2026.
Is Boston Scientific's Long-Term Debt too high?
Boston Scientific's current Long-Term Debt is R$55,294 Mil. Overall, Boston Scientific has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Long-Term Debt compare to EW and DXCM?
Boston Scientific's Long-Term Debt of R$55,294 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Boston Scientific's current Long-Term Debt is R$55,294 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSP:B1SX34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$137.33, compared to a current price of R$67.48 — trading 50.9% below its estimated fair value. The current Long-Term Debt is R$55,294 Mil. Boston Scientific's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Boston Scientific (BSP:B1SX34), the current Long-Term Debt is R$55,294 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (BSP:B1SX34) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of R$67.48 is trading 50.9% below its estimated GF Value™ of R$137.33. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for BSP:B1SX34:

  • Long-Term Debt: R$55,294 Mil
  • GF Value™: R$137.33 vs. price of R$67.48 (50.9% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the BSP:B1SX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
80GF Score

Get the complete analysis for BSP:B1SX34

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$67.48
Price
R$137.33
GF Value